Regencell Bioscience Holdings Limited (RGC)
Last Price$41.0(30.1%)
Market Cap$533.5M
RGC Rating
RGC Quality rating performance
RGC Intrinsic Value
Key Highlights:
As of Mar 24, 2025 RGC Relative Value is $0.6, which is overvalued by 98.5%, compared to current share price of $41.0.
As of Mar 24, 2025 RGC DCF Value is N/A, which is undervalued by N/A, compared to current share price of $41.0.
RGC Share Price History
1W 121.6%
1M 795.2%
6M 603.3%
YTD 290.5%
1Y 1,008.1%
3Y 33.7%
5Y 290.5%
10Y 290.5%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
RGC Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$533.5M
$525.7M
$0.0
Shares Outstanding
13M
Employees
N/A
Growth (CAGR)
(100.0%)
N/A
(100.0%)
Profitability
Intrinsic Value
$0.6 (98.5% overvalued)
N/A
$0.6
N/A
Return on Capital
Financial Health
$7,961.2K
($7,875.5K)
Dividends
Earnings
Mar 26, 2025
undefined by N/A
undefined by N/A
undefined Beat & undefined Miss
RGC Stock Financials
RGC Income Statement Metrics
Annual
Quarterly
LTM
RGC Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($4,001.7K) -100.0% YoY
Capital Expenditure (CAPEX)
($5,376.0) N/A YoY
Free Cash Flow (FCF)
($4,007.1K) -100.0% YoY
RGC Income Statement Overview
Annual
Quarterly
LTM
Jan'15
Dec'15
Dec'16
Dec'17
Jun'19
Jun'20
Jun'21
Jun'22
Jun'23
Jun'24
RGC Balance Sheet Overview
Annual
Quarterly
LTM
Jan'15
Dec'15
Dec'16
Dec'17
Jun'19
Jun'20
Jun'21
Jun'22
Jun'23
Jun'24
Assets
Liabilities
Total assets
$8,438.2K
Current assets ($8,114.0K, 96.2% of total)
$7,961.2K (94.3%)
$152.8K (1.8%)
Other current assets
$0.0 (0.0%)
Non-current assets ($324.2K, 3.8% of total)
$0.0 (0.0%)
$226.5K (2.7%)
$0.0 (0.0%)
Other non-current assets
$97.7K (1.2%)
Financial position
($7,875.5K)
Cash & Short-term
Investments
Total Debt
RGC Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
RGC Earnings Surprises
Crunching data... Almost there!
RGC Dividends
RGC Dividend Yield
Crunching data... Almost there!
RGC Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with RGC
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$533.5M | 5.0 | $0.6 98.5% overvalued | 1,008.1% | $0.0 | $0.0 | N/A | N/A | N/A | (623.7%) | 1.0% | |
$74.1B | 6.9 | $88.0 46.0% overvalued | (1.7%) | $9,256.0M | $2,298.0M | 8.3% | 24.8% | 69.8% | 18.5% | 141.4% | |
$47.5B | 6.4 | $47.9 219.5% undervalued | 10.9% | ¥4,546.1B | ¥508.6B | 9.4% | 11.2% | 55.2% | 4.1% | 73.0% | |
$46.7B | 5.6 | $13.7 35.4% undervalued | 20.9% | £11.2B | £0.0 | (0.6%) | 0.0% | 62.6% | 12.1% | 63.4% | |
$18.3B | 6.3 | $33.7 108.1% undervalued | 15.1% | $16.6B | $1,361.0M | 4.5% | 8.2% | 48.8% | 2.6% | 316.1% | |
$13.6B | 5.1 | $29.1 77.9% overvalued | 93.8% | $680.6M | ($73.5M) | 47.3% | (10.8%) | 91.6% | (65.8%) | 1.5% | |
$11.6B | 7.7 | $108.3 6.4% overvalued | (17.6%) | $2,355.3M | $557.2M | 24.8% | 23.7% | 98.1% | 46.7% | 17.6% | |
$11.6B | 5.6 | $29.3 53.9% overvalued | 51.5% | $4,422.0M | $99.0M | 4.4% | 2.2% | 21.8% | (0.1%) | 139.7% | |
$11.4B | 6.1 | $12.5 9.1% overvalued | (6.2%) | ₹311.3B | ₹6,517.0M | 14.7% | 2.1% | 59.3% | 15.0% | 15.9% | |
$11.1B | 5.4 | $47.5 411.1% undervalued | (17.9%) | $14.7B | $1,963.9M | (4.5%) | 13.3% | 38.5% | (0.4%) | 76.8% | |
$6,882.9M | 7.8 | $55.6 44.1% overvalued | 68.5% | $1,533.9M | $493.1M | 18.3% | 32.1% | 65.1% | 42.8% | 0.1% |
FAQ
What is Regencell Bioscience Holdings Limited (RGC) stock rating?
As of today, Regencell Bioscience Holdings Limited has a stock rating of N/A (out of 10), which is considered Great.
is Regencell Bioscience Holdings Limited (RGC) a good stock to buy?
As of today, Regencell Bioscience Holdings Limited has a Great stock rating, which is N/A undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 12.8%.